A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
NCT06344728 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2024-06-13
Summary
The primary purpose of this study is to determine the relative bioavailability of brensocatib between the pediatric oral solution and oral tablets in healthy participants.
Conditions
- Healthy Participants
Interventions
- DRUG
-
Brensocatib Oral Solution
Brensocatib solution
- DRUG
-
Brensocatib Oral Tablet
Brensocatib tablet
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-04-30
- Primary Completion
- 2024-05-24
- Completion
- 2024-05-24
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
NCT06941077 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects
NCT02875080 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets
NCT05327491 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants
NCT05303220 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers
NCT02214927 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers
NCT02183298 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects
NCT02173665 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects
NCT03123185 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS
NCT02180503 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
NCT02068690 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects
NCT02999191 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
NCT01366352 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants
NCT03035734 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants
NCT02930694 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
NCT07226817 ·Status: RECRUITING ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
NCT02044406 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers
NCT02161432 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Tolerability and Pharmacokinetic of BI 409306
NCT01343706 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers
NCT02215018 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers
NCT02214914 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers
NCT02183441 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects
NCT01195688 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants
NCT03943056 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects
NCT02000765 ·Status: COMPLETED ·Phase: PHASE1
-
Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations
NCT04814472 ·Status: COMPLETED ·Phase: PHASE1